Literature DB >> 23721804

Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.

Yan Zhang1, Orgil Elbegdorj, Yunyun Yuan, Irina O Beletskaya, Dana E Selley.   

Abstract

Isosterism is commonly used in drug discovery and development to address stability, selectivity, toxicity, pharmacokinetics, and efficacy issues. A series of 14-O-substituted naltrexone derivatives were identified as potent mu opioid receptor (MOR) antagonists with improved selectivity over the kappa opioid receptor (KOR) and the delta opioid receptor (DOR), compared to naltrexone. Since esters are not metabolically very stable under typical physiological conditions, their corresponding amide analogs were thus synthesized and biologically evaluated. Unlike their isosteres, most of these novel ligands seem to be dually selective for the MOR and the KOR over the DOR. The restricted flexibility of the amide bond linkage might be responsible for their altered selectivity profile. However, the majority of the 14-N-substituted naltrexone derivatives produced marginal or no MOR stimulation in the (35)S-GTP[γS] assay, which resembled their ester analogs. The current study thus indicated that the 14-substituted naltrexone isosteres are not bioisosteres since they have distinctive pharmacological profile with the regard to their opioid receptor binding affinity and selectivity. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23721804      PMCID: PMC3690547          DOI: 10.1016/j.bmcl.2013.05.027

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  33 in total

1.  Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.

Authors:  P S Portoghese; M Sultana; H Nagase; A E Takemori
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

2.  Affinity labels as probes for opioid receptor types and subtypes.

Authors:  P S Portoghese; A E Takemori
Journal:  NIDA Res Monogr       Date:  1986

3.  Novel analgesics and molecular rearrangements in the morphine-thebaine group. XVI. Some derivatives of 6,14-endo-etheno-7, 8-dihydromorphine.

Authors:  K W Bentley; J D Bower; J W Lewis
Journal:  J Chem Soc Perkin 1       Date:  1969

4.  Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.

Authors:  A Márki; K Monory; F Otvös; G Tóth; R Krassnig; H Schmidhammer; J R Traynor; B P Roques; R Maldonado; A Borsodi
Journal:  Eur J Pharmacol       Date:  1999-10-27       Impact factor: 4.432

Review 5.  Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose.

Authors:  Alison J Ritter
Journal:  Aust N Z J Psychiatry       Date:  2002-04       Impact factor: 5.744

6.  Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.

Authors:  J H Broadbear; T L Sumpter; T F Burke; S M Husbands; J W Lewis; J H Woods; J R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

Review 7.  Naltrexone and dysphoria: fact or myth?

Authors:  Karen Miotto; Michael McCann; Janice Basch; Richard Rawson; Walter Ling
Journal:  Am J Addict       Date:  2002

Review 8.  Consensus statement on office-based treatment of opioid dependence using buprenorphine.

Authors:  David A Fiellin; Herbert Kleber; Jeanne G Trumble-Hejduk; A Thomas McLellan; Thomas R Kosten
Journal:  J Subst Abuse Treat       Date:  2004-09

9.  Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.

Authors:  Yunyun Yuan; Orgil Elbegdorj; Jianyang Chen; Shashidhar K Akubathini; Feng Zhang; David L Stevens; Irina O Beletskaya; Krista L Scoggins; Zhenxian Zhang; Phillip M Gerk; Dana E Selley; Hamid I Akbarali; William L Dewey; Yan Zhang
Journal:  J Med Chem       Date:  2012-11-09       Impact factor: 7.446

10.  Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.

Authors:  Mariana Spetea; Falko Schüllner; Radu C Moisa; Ilona P Berzetei-Gurske; Barbara Schraml; Cynthia Dörfler; Mario D Aceto; Louis S Harris; Andrew Coop; Helmut Schmidhammer
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

View more
  4 in total

1.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

2.  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Authors:  Yunyun Yuan; Saheem A Zaidi; David L Stevens; Krista L Scoggins; Philip D Mosier; Glen E Kellogg; William L Dewey; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-06       Impact factor: 3.641

3.  Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors.

Authors:  Boshi Huang; Rama Gunta; Huiqun Wang; Mengchu Li; Danni Cao; Rolando E Mendez; James C Gillespie; Chongguang Chen; Lan-Hsuan M Huang; Lee-Yuan Liu-Chen; Dana E Selley; Yan Zhang
Journal:  Bioorg Chem       Date:  2021-02-09       Impact factor: 5.275

4.  Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors.

Authors:  Qianwei Shen; Yulin Deng; Roberto Ciccocioppo; Nazzareno Cannella
Journal:  Front Psychiatry       Date:  2017-11-13       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.